《新股表现》心通医疗(02160.HK)暗盘高开64%报20元
根据辉立交易平台显示,明天挂牌的微创心通医疗科技-B(02160.HK)暗盘高开64%报20元获承接,最高见21.15元,现造19.5元,较上市价12.2元,高61%;成交523万股。
微创心通由微创医疗(00853.HK)分拆上市,公司专注於心脏瓣膜疾病领域创新的经导管及手术解决方案的研发和商业化。是次上市共发售2.06亿股,并已包括源峰基金、Hillhouse Funds、GIC、雪湖资本及华夏基金等16名基石投资者,合共认购7,943.3万股;其中10%公开发售获768倍超购,已启动回拨机制占比增至50%,认购一手中签率仅7.5%;股份以招股范围(11.1-12.2元)上限定价,料集资净额约23.56亿元,主要用作核心产品VitaFlow II、用於微创心通首款商业化TAVI产品VitaFlow、用作现有产品管线的其他产品、透过并购和授权引进安排或股权投资与包括医疗器械企业及研究机构在内全球赋能者合作扩展集团产品组合提供资金、扩大产能并提高生产VitaFlow及VitaFlow II能力等。上市联席保荐人分别为大摩、花旗及中金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.